Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis

Journal of the American Academy of Dermatology, 2016 07. e-pub ahead of print 2016/08/02

We sought to compare apremilast's relative efficacy with that of methotrexThere was no statistical evidence of greater efficacy for apremilast versus methotrexate. The $187,888 incremental cost per PASI 75 may exceed what payers are willing to pay.ate for moderate to severe psoriasis.

View abstract


Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.